We're a company founded to improve outcomes for patients with cancer.
ImmVirX seeks to advance a new generation of cancer treatments by developing a novel oncolytic immunotherapy that targets cancer indications with high unmet need.
Company Overview
ImmVirX was founded in July 2019 by the team from Viralytics, a clinical-stage ASX-listed oncolytic virus company acquired in June 2018 by Merck and Co. Inc. for A$502 million. We are developing proprietary bio-selected RNA viruses with the capacity to selectively infect and kill cancer cells while also inducing tumour inflammation and achieving immune cell infiltration – potentially leading to the generation of specific innate and adaptive immune responses against cancer cells.
Our viral candidates are intended to increase the anti-tumour activity of current cancer immunotherapies, including immune checkpoint inhibitors, CAR-Ts and other cell therapies, and are targeted against a range of difficult-to-treat cancers, including colorectal, gastric, hepatocellular and ovarian cancer.
Our Facilities
R&D Facilities
Our team is based in state-of-the-art R&D facilities at the Hunter Medical Research Institute (HMRI) and is supported by the University of Newcastle Research Associates (TUNRA) in Newcastle, New South Wales, Australia.
Our Team
Board & Management
The ImmVirX team comprises key directors and the executive and scientific staff from Viralytics.
Leveraging our leadership and experience in oncolytic viral therapies, we are building a body of pre-clinical and manufacturing data with the goal of conducting early-stage clinical trials in 2022.
